Lv31
378 积分 2022-11-07 加入
Trends in the development of cellular and gene therapy in China
2小时前
已完结
The rise of China’s pharmaceutical industry from 2015–2024: a decade of innovation
12天前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
16天前
已完结
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis
19天前
已完结
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis
19天前
已完结
Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials
19天前
已完结
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
19天前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
19天前
已完结
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
20天前
已完结
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
20天前
已完结
皖公网安备34019202002308
